# Nitric oxide immune dependent resistance mechanisms to anti-PD-1 therapy

> **NIH NIH K08** · H. LEE MOFFITT CANCER CTR & RES INST · 2023 · $209,852

## Abstract

Project Summary/Abstract
I, Joseph Markowitz, MD PhD, am a junior medical oncologist at Moffitt Cancer Center interested in developing
immune-based therapeutics for the benefit of melanoma patients. Moffitt is the ideal environment for me to
develop into an independent physician scientist given the dedicated Moffitt’s Melanoma and Skin Cancers Center
of Excellence, superb flow cytometry core, extensive clinical trial support infrastructure, and highly supportive
bioinformatics and biostatistics core. Immune-based therapy has had mounting successes in the past few years
with the introduction of checkpoint inhibitors. However, many patients do not respond to therapy, and I intend to
dedicate my career into turning these failures into successes. I will have the mentorship to adapt and grow with
the project. My mentorship team (Drs. Mulé, Sondak, Conejo-Garcia, Tarhini, and Berglund) was carefully
selected to include translational and clinical mentors to ensure that I can mature into a successful immuno-
oncologist for therapeutic development in melanoma. Melanoma cells protect themselves from immune attack
by releasing factors that stimulate development of immune suppressor cells. Immune suppressor cells, such as
myeloid-derived suppressor cells (MDSCs), release large amounts of nitric oxide (NO) that inactivate proteins
that normally help immune cells sense and respond to cancer. Hypothesis: Anti-PD-1 resistance in melanoma
results, in part, from reduction of DC antigen presentation to T cells via a NO dependent mechanism.
Furthermore, NO causes nitration of multiple proteins including STAT1 and NFκB as well as MHC and T-cell
receptor (TCR) molecules expressed by immune cells such as dendritic cells (DC), making them less effective
for transmitting signals crucial for antigen presentation and rejection of tumors. Therefore, this proposal outlines
a series of experiments that will: 1) use murine and ex-vivo models to measure antigen presentation from DC to
T cells to elucidate the operative mechanism(s) by which nitration of antigen presentation proteins such as
STAT1 results in immune tolerance to melanoma and resistance to anti-PD-1 therapy and to follow the levels of
MDSCs, nitric oxide, and nitric oxide producing MDSCs over the course of treatment using multidimensional flow
cytometry, and 2) access to well-annotated tissue specimens from melanoma patients receiving anti-PD-1
treatment (unresectable stage III/IV) to quantify the effects of NO and correlate this with changes in immune cell
responses to interferon, as well as mRNA and proteomics profiles. Work completed in this proposal will
potentially enable the development of new therapeutic strategies to overcome the inhibitory effects of nitric oxide
and enhance patient immune responses to melanoma with anti-PD-1 therapy (and potentially other immune-
based therapies). In addition, this proposal may lead to new quantitative mass spectrometry and bioinformatics
methods to predict who will resp...

## Key facts

- **NIH application ID:** 10694871
- **Project number:** 5K08CA252164-03
- **Recipient organization:** H. LEE MOFFITT CANCER CTR & RES INST
- **Principal Investigator:** JOSEPH MARKOWITZ
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $209,852
- **Award type:** 5
- **Project period:** 2021-09-01 → 2024-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10694871

## Citation

> US National Institutes of Health, RePORTER application 10694871, Nitric oxide immune dependent resistance mechanisms to anti-PD-1 therapy (5K08CA252164-03). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10694871. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*